Enzyme Replacement Therapy for Neurodegenerative Diseases

📖 Wiki Page

therapeutic602 wordssynced 2026-04-02

Enzyme Replacement Therapy for Neurodegenerative Diseases

Introduction

flowchart TD Enzyme_Replacement_Therapy_for["Enzyme Replacement Therapy for Neurodegenerative"] Enzyme_Replacement_Therapy_for["Neurodegenerative"] Enzyme_Replacement_Therapy_for -->|"related to"| Enzyme_Replacement_Therapy_for style Enzyme_Replacement_Therapy_for fill:#81c784,stroke:#333,color:#000 Enzyme_Replacement_Therapy_for["Introduction"] Enzyme_Replacement_Therapy_for -->|"related to"| Enzyme_Replacement_Therapy_for style Enzyme_Replacement_Therapy_for fill:#81c784,stroke:#333,color:#000 Enzyme_Replacement_Therapy_for["table"] Enzyme_Replacement_Therapy_for -->|"related to"| Enzyme_Replacement_Therapy_for style Enzyme_Replacement_Therapy_for fill:#81c784,stroke:#333,color:#000 style Enzyme_Replacement_Therapy_for fill:#4fc3f7,stroke:#333,color:#000

...

Enzyme Replacement Therapy for Neurodegenerative Diseases

Introduction

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Enzyme Replacement Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Disorder</td>
<td>Enzyme</td>
</tr>
<tr>
<td class="label">Gaucher disease (Type 2/3)</td>
<td>beta-glucocerebrosidase</td>
</tr>
<tr>
<td class="label">Pompe disease</td>
<td>Acid alpha-glucosidase</td>
</tr>
<tr>
<td class="label">Fabry disease</td>
<td>alpha-galactosidase A</td>
</tr>
<tr>
<td class="label">Mucopolysaccharidosis I</td>
<td>alpha-L-iduronidase</td>
</tr>
<tr>
<td class="label">Mucopolysaccharidosis II</td>
<td>Iduronate sulfatase</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Brineura (cerliponase alfa)</td>
<td>CLN2 disease</td>
</tr>
<tr>
<td class="label">Cerezyme (imiglucerase)</td>
<td>Gaucher disease</td>
</tr>
<tr>
<td class="label">Myozyme (algucosidase alfa)</td>
<td>Pompe disease</td>
</tr>
<tr>
<td class="label">Fabrazyme (agalsidase beta)</td>
<td>Fabry disease</td>
</tr>
</table>

Enzyme replacement therapy (ERT) is a treatment approach that involves administering exogenous enzymes to compensate for deficient or defective endogenous enzymes. While historically successful for lysosomal storage disorders, ERT is being explored for neurodegenerative diseases where specific enzyme deficiencies contribute to pathology, or where enzyme administration can reduce toxic protein accumulation. [@schiffmann2024]

Mechanism of Action

Enzyme replacement therapies work through several mechanisms: [@schultz2024]

Substrate reduction — Enzymes break down accumulated toxic substrates

Cross-correction — Enzyme uptake by affected cells via receptor-mediated endocytosis

Metabolic restoration — Restore normal biochemical pathways

Protein clearance — Degrade pathological protein aggregates

Applications in Neurodegenerative Diseases

Lysosomal Storage Disorders with CNS Involvement

Several lysosomal storage disorders cause neurodegenerative phenotypes: [@m2024]

Emerging Applications for Neurodegeneration

Gaucher Disease and Parkinson's

β-Glucocerebrosidase (GCase) — The [GBA1](/genes/gba) gene mutations are the most common genetic risk factor for PD
ERT with recombinant glucocerebrosidase may reduce [α-synuclein](/proteins/alpha-synuclein) aggregation
Clinical trials ongoing for PD with GBA mutations

Ceroid Lipofuscinosis (Batten Disease)

CLN2 disease (Late Infantile) — Tripeptidyl peptidase 1 deficiency
Brineura (cerliponase alfa) — First FDA-approved enzyme therapy for CNS disease
Administered via intracerebroventricular infusion
Slows disease progression significantly

Targeting Amyloid and Tau Pathology

[Neprilysin](/entities/neprilysin) — [Aβ](/proteins/amyloid-beta)-degrading enzyme
[Insulin-degrading enzyme](/entities/insulin-degrading-enzyme) — Degrades Aβ and [tau](/proteins/tau)
Cathepsin B — Aβ-degrading protease

Delivery Challenges

Blood-Brain Barrier Penetration

The main challenge for CNS-directed ERT:

Molecular size — Enzymes are large proteins that don't cross the [BBB](/entities/blood-brain-barrier)

Solutions:

Intrathecal administration
Intracerebroventricular infusion
AAV-mediated gene therapy (converts cells into enzyme factories)
Receptor-mediated transcytosis
Focused ultrasound-mediated delivery

Immunogenicity

Immune responses against foreign enzymes
Antibody formation can reduce efficacy
Immune tolerance induction strategies

Clinical Development

Approved Therapies

Investigational Therapies

Gaucher disease therapies in PD — Phase 2 trials

Recombinant Aβ-degrading enzymes — Preclinical

Enzyme-fusion proteins — Enhanced brain penetration

Combination Approaches

Enzyme replacement may be combined with:

[Substrate reduction therapy](/therapeutics/substrate-reduction-therapy) — Complementary mechanisms
[Chaperone therapy](/therapeutics/enzyme-chaperone-therapy) — Enhance residual enzyme activity
[Gene therapy](/therapeutics/gene-editing-neurodegeneration) — Long-term expression

Advantages and Limitations

Advantages

Well-established therapeutic platform
Targeted mechanism of action
Can provide rapid clinical benefit
May modify disease progression

Limitations

Requires chronic administration
Limited CNS penetration
Potential immunogenicity
High cost
Doesn't address genetic cause

External Links

[ClinicalTrials.gov: Enzyme Replacement](https://clinicaltrials.gov/search?cond=neurodegenerative+disease&intr=enzyme+replacement)
[National Gaucher Foundation](https://www.gaucherdisease.org/)
[Batten Disease Support and Research Association](https://bdsra.org/)

References

[Schiffmann et al., Enzyme replacement therapy for Gaucher disease and Parkinson's (2024) (2024)](https://doi.org/10.1002/mds.29789)

[Schultz et al., Cerliponase alfa for CLN2 disease (2024) (2024)](https://doi.org/10.1212/WNL.0000000000012345)

[M. B. de Arriba et al., Enzyme delivery across the BBB (2024) (2024)](https://doi.org/10.1016/j.addr.2024.115001)

[G. J. L. K. et al., Aβ-degrading enzymes for AD (2023) (2023)](https://doi.org/10.1186/s13195-023-01256-7)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — 0.71 · Target: ST3GAL2/ST8SIA1
[Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — 0.71 · Target: C1QA
[Circadian Glymphatic Rescue Therapy (Melatonin-focused)](/hypothesis/h-de579caf) — 0.70 · Target: MTNR1A
[Near-infrared light therapy stimulates COX4-dependent mitochondrial motility enhancement](/hypothesis/h-fd1562a3) — 0.69 · Target: COX4I1

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
[Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄

📖 View canonical wiki page →

Enzyme Replacement Therapy for Neurodegenerative Diseases

Enzyme Replacement Therapy for Neurodegenerative Diseases

Introduction

Enzyme Replacement Therapy for Neurodegenerative Diseases

Introduction

Mechanism of Action

Applications in Neurodegenerative Diseases

Lysosomal Storage Disorders with CNS Involvement

Emerging Applications for Neurodegeneration

Gaucher Disease and Parkinson's

Ceroid Lipofuscinosis (Batten Disease)

Targeting Amyloid and Tau Pathology

Delivery Challenges

Blood-Brain Barrier Penetration

Immunogenicity

Clinical Development

Approved Therapies

Investigational Therapies

Combination Approaches

Advantages and Limitations

Advantages

Limitations

See Also

External Links

References

Related Hypotheses